Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness

Oncotarget

Volumn 6, Issue 5, 2015, Pages 3111-3122

  Zhou, Xuefeng ^a   Li, Dan ^a   Wang, Xianguo ^a   Zhang, Bo ^b   Zhu, Hua ^b   Zhao, Jinping ^a  

^a WUHAN UNIVERSITY   (China)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Cancer stem cells; CD133; Galectin 1; Lung adenocarcinoma

Indexed keywords

CD133 ANTIGEN; CYCLOOXYGENASE 2; GALECTIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROSTAGLANDIN E2; PROTEIN KINASE B; SMALL INTERFERING RNA; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; PROM1 PROTEIN, HUMAN; PROM1 PROTEIN, MOUSE; TUMOR MARKER;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER STEM CELL; COLONY FORMATION; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; FEMALE; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; BLOOD; CANCER TRANSPLANTATION; CELL MOTION; CELL PROLIFERATION; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RNA INTERFERENCE; SCID MOUSE; TIME FACTOR; TUMOR CELL CULTURE; TUMOR VOLUME; UPREGULATION;

AC133 ANTIGEN; ADENOCARCINOMA; ADULT; AGED; ANIMALS; ANTIGENS, CD; BIOMARKERS, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GALECTIN 1; GENE KNOCKDOWN TECHNIQUES; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MICE, SCID; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PEPTIDES; RETROSPECTIVE STUDIES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84923275569     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3076     Document Type: Article

References (59)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30.
2. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-550.
3. Herbst RS, Heymach JV and Lippman SM. Lung cancer. N Engl J Med. 2008; 359(13):1367-1380.
4. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004; 64(24):8919-8923.
5. Petersen I and Petersen S. Towards a genetic-based classification of human lung cancer. Anal Cell Pathol. 2001; 22(3):111-121.
6. Collins LG, Haines C, Perkel R and Enck RE. Lung cancer: diagnosis and management. Am Fam Physician. 2007; 75(1):56-63.
7. Nguyen LV, Vanner R, Dirks P and Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012; 12(2):133-143.
8. Visvader JE and Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8(10):755-768.
9. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G and Pirozzi G. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg. 2009; 36(3):446-453.
10. Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S, Soh BS, Sun LL, Tai BC, Nga ME, Bhakoo KK, Jayapal SR, Nichane M, Yu Q, Ahmed DA, Tan C, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell. 2012; 148(1-2):259-272.
11. Ricci-Vitiani L, Fabrizi E, Palio E and De Maria R. Colon cancer stem cells. J Mol Med (Berl). 2009; 87(11):1097-1104.
12. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ and Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci. 2004; 117(Pt 16):3539-3545.
13. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008; 15(3):504-514.
14. Wiwanitkit V. CD133 and non-small-cell lung cancer. Eur J Cardiothorac Surg. 2010; 37(4):988; author reply 988-989.
15. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-760.
16. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ and Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007; 1(3):313-323.
17. Camby I, Le Mercier M, Lefranc F and Kiss R. Galectin-1: a small protein with major functions. Glycobiology. 2006; 16(11):137R-157R.
18. Thijssen VL, Barkan B, Shoji H, Aries IM, Mathieu V, Deltour L, Hackeng TM, Kiss R, Kloog Y, Poirier F and Griffioen AW. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res. 2010; 70(15):6216-6224.
19. Masamune A, Satoh M, Hirabayashi J, Kasai K, Satoh K and Shimosegawa T. Galectin-1 induces chemokine production and proliferation in pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2006; 290(4):G729-736.
20. Rabinovich GA, Alonso CR, Sotomayor CE, Durand S, Bocco JL and Riera CM. Molecular mechanisms implicated in galectin-1-induced apoptosis: activation of the AP-1 transcription factor and downregulation of Bcl-2. Cell Death Differ. 2000; 7(8):747-753.
21. Chung LY, Tang SJ, Sun GH, Chou TY, Yeh TS, Yu SL and Sun KH. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res. 2012; 18(15):4037-4047.
22. Kuo PL, Hung JY, Huang SK, Chou SH, Cheng DE, Jong YJ, Hung CH, Yang CJ, Tsai YM, Hsu YL and Huang MS. Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway. J Immunol. 2011; 186(3):1521-1530.
23. Lee MY, Lee SH, Park JH and Han HJ. Interaction of galectin-1 with caveolae induces mouse embryonic stem cell proliferation through the Src, ERas, Akt and mTOR signaling pathways. Cell Mol Life Sci. 2009; 66(8):1467-1478.
24. Kim KW, Moretti L, Mitchell LR, Jung DK and Lu B. Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model. Clin Cancer Res. 2009; 15(19):6096-6105.
25. Pisick E, Jagadeesh S and Salgia R. Receptor tyrosine kinases and inhibitors in lung cancer. ScientificWorldJournal. 2004; 4:589-604.
26. Qu H, Li R, Liu Z, Zhang J and Luo R. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol. 2013; 6(11):2644-2650.
27. Desai A, Webb B and Gerson SL. CD133+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells. Radiother Oncol. 2014; 110(3):538-545.
28. Chen Y, Yu D, Zhang H, He H, Zhang C, Zhao W and Shao RG. CD133(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells. Int J Biol Sci. 2012; 8(7):992-1004.
29. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A. 2009; 106(38):16281-16286.
30. Wu H, Qi XW, Yan GN, Zhang QB, Xu C and Bian XW. Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis. PLoS One. 2014; 9(6):e100168.
31. Sun Z, Wang Z, Liu X and Wang D. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. Anticancer Drugs. 2014.
32. Fumarola C, Bonelli MA, Petronini PG and Alfieri RR. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol. 2014; 90(3):197-207.
33. Liao Z and Milas L. COX-2 and its inhibition as a molecular target in the prevention and treatment of lung cancer. Expert Rev Anticancer Ther. 2004; 4(4):543-560.
34. Sandler AB and Dubinett SM. COX-2 inhibition and lung cancer. Semin Oncol. 2004; 31(2 Suppl 7):45-52.
35. Li F, Tiede B, Massague J and Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 2007; 17(1):3-14.
36. Zhu J, Ding J and Ding F. Tumor stem cell, or its niche, which plays a primary role in tumorigenesis? World J Gastrointest Oncol. 2010; 2(5):218-221.
37. Vidal SJ, Rodriguez-Bravo V, Galsky M, Cordon-Cardo C and Domingo-Domenech J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene. 2014; 33(36):4451-4463.
38. Kim Y, Joo KM, Jin J and Nam DH. Cancer stem cells and their mechanism of chemo-radiation resistance. Int J Stem Cells. 2009; 2(2):109-114.
39. Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 2007; 67(19):8980-8984.
40. Croker AK and Allan AL. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44(+) human breast cancer cells. Breast Cancer Res Treat. 2012; 133(1):75-87.
41. Vinogradov S and Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond). 2012; 7(4):597-615.
42. Strik HM, Schmidt K, Lingor P, Tonges L, Kugler W, Nitsche M, Rabinovich GA and Bahr M. Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration. Oncol Rep. 2007; 18(2):483-488.
43. Stannard KA, Collins PM, Ito K, Sullivan EM, Scott SA, Gabutero E, Darren Grice I, Low P, Nilsson UJ, Leffler H, Blanchard H and Ralph SJ. Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model. Cancer Lett. 2010; 299(2):95-110.
44. Sakaguchi M, Shingo T, Shimazaki T, Okano HJ, Shiwa M, Ishibashi S, Oguro H, Ninomiya M, Kadoya T, Horie H, Shibuya A, Mizusawa H, Poirier F, Nakauchi H, Sawamoto K and Okano H. A carbohydrate-binding protein, Galectin-1, promotes proliferation of adult neural stem cells. Proc Natl Acad Sci U S A. 2006; 103(18):7112-7117.
45. Lee MY and Han HJ. Galectin-1 upregulates glucose transporter-1 expression level via protein kinase C, phosphoinositol-3 kinase, and mammalian target of rapamycin pathways in mouse embryonic stem cells. Int J Biochem Cell Biol. 2008; 40(11):2421-2430.
46. Menon S and Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene. 2008; 27 Suppl 2:S43-51.
47. Sharma-Walia N, Patel K, Chandran K, Marginean A, Bottero V, Kerur N and Paul AG. COX-2/PGE2: molecular ambassadors of Kaposi's sarcoma-associated herpes virus oncoprotein-v-FLIP. Oncogenesis. 2012; 1:e5.
48. Xiao Y, Teng Y, Zhang R and Luo L. Antitumor effect of the selective COX-2 inhibitor celecoxib on endometrial adenocarcinoma in vitro and in vivo. Oncol Lett. 2012; 4(6):1219-1224.
49. Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, Schwarz RE, Burrows FJ and Brekken RA. Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clin Cancer Res. 2012; 18(18):5031-5042.
50. Xu L, Stevens J, Hilton MB, Seaman S, Conrads TP, Veenstra TD, Logsdon D, Morris H, Swing DA, Patel NL, Kalen J, Haines DC, Zudaire E and St Croix B. COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci Transl Med. 2014; 6(242):242ra284.
51. Zaytseva YY, Valentino JD, Gulhati P and Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett. 2012; 319(1):1-7.
52. Sparks CA and Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene. 2010; 29(26):3733-3744.
53. Gridelli C, Maione P and Rossi A. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist. 2008; 13(2):139-147.
54. Sarissky M, Lavicka J, Kocanova S, Sulla I, Mirossay A, Miskovsky P, Gajdos M, Mojzis J and Mirossay L. Diazepam enhances hypericin-induced photocytotoxicity and apoptosis in human glioblastoma cells. Neoplasma. 2005; 52(4):352-359.
55. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Black KL and Yu JS. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 2004; 23(58):9392-9400.
56. Li W, Jian-jun W, Xue-Feng Z and Feng Z. CD133(+) human pulmonary adenocarcinoma cells induce apoptosis of CD8(+) T cells by highly expressed galectin-3. Clin Invest Med. 2010; 33(1):E44-53.
57. Fortin S, Le Mercier M, Camby I, Spiegl-Kreinecker S, Berger W, Lefranc F and Kiss R. Galectin-1 is implicated in the protein kinase C epsilon/vimentin-controlled trafficking of integrin-beta1 in glioblastoma cells. Brain Pathol. 2010; 20(1):39-49.
58. Le Mercier M, Lefranc F, Mijatovic T, Debeir O, Haibe-Kains B, Bontempi G, Decaestecker C, Kiss R and Mathieu V. Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol. 2008; 229(2):172-183.
59. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q and Hong W. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 2008; 68(8):2592-2598.